A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way

Review Will Determine Whether Access To Biogen's SMA Treatment Will Be Expanded

 
• By Francesca Bruce

NICE will review new data in deciding whether to OK the use of Spinraza in non-ambulant SMA type III patients.

Early morning sky background, sunlight through white clouds and free birds flying away
Interim review could expand access to Spinraza

More from Europe

More from Geography